Cargando…

Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

B-Raf(V600E) activates MEK/MAPK signalling and acts as oncogenic driver of a variety of cancers, including melanoma, colorectal and papillary thyroid carcinoma. Specific B-Raf(V600E) kinase inhibitors (e.g., Vemurafenib) prove initial efficacy in melanoma followed shortly by acquired resistance, whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atiq, Rawan, Hertz, Rachel, Eldad, Sophia, Smeir, Elia, Bar-Tana, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951321/ https://www.ncbi.nlm.nih.gov/pubmed/26959890 http://dx.doi.org/10.18632/oncotarget.7909

Ejemplares similares

Suppression of multiple myeloma by mitochondrial targeting
por: Aisen, Yana, et al.
Publicado: (2021)

Treatment of ErbB2 breast cancer by mitochondrial targeting
por: Eldad, Sophia, et al.
Publicado: (2020)

The mechanism of activation of monomeric B-Raf V600E
por: Maloney, Ryan C., et al.
Publicado: (2021)

Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants
por: Zhang, Mingzhen, et al.
Publicado: (2022)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

Harmine suppresses hyper-activated Ras–MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in Caenorhabditis elegans
por: Ji, Jiaojiao, et al.
Publicado: (2019)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

Novel natural inhibitors targeting B-RAF(V600E) by computational study
por: Wu, Bo, et al.
Publicado: (2021)

Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
por: Shi, Hubing, et al.
Publicado: (2012)

A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer
por: Caputo, Emilia
Publicado: (2017)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Discovery of New Quinolone-Based Diarylamides as Potent B-RAF(V600E)/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity
por: Kim, Hyun Ji, et al.
Publicado: (2023)

Apoptosis of human melanoma cells induced by inhibition of B-RAF(V600E) involves preferential splicing of bim(S)
por: Jiang, C C, et al.
Publicado: (2010)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1
por: Choi, Yong Won, et al.
Publicado: (2014)

BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
por: Obasaju, Patience, et al.
Publicado: (2020)

A B‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies
por: Yao, Kevin, et al.
Publicado: (2022)

The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury
por: Li, J-X, et al.
Publicado: (2014)

Oncogenic B-RAF(V600E) signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion
por: Boyd, Suzanah C., et al.
Publicado: (2012)

TSH Signaling Overcomes B-RafV600E–Induced Senescence in Papillary Thyroid Carcinogenesis through Regulation of DUSP6()()
por: Kim, Young Hwa, et al.
Publicado: (2014)

Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors via docking and bioassay
por: Li, Yisu, et al.
Publicado: (2016)

Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies
por: Anbar, Hanan S., et al.
Publicado: (2020)

Sprouty2 regulates positioning of retinal progenitors through suppressing the Ras/Raf/MAPK pathway
por: Sun, Jian, et al.
Publicado: (2020)

Expression of B-RAF V600E in Type II Pneumocytes Causes Abnormalities in Alveolar Formation, Airspace Enlargement and Tumor Formation in Mice
por: Zanucco, Emanuele, et al.
Publicado: (2011)

The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia
por: Guerrini, Francesca, et al.
Publicado: (2016)

Critical role of miR-10b in B-Raf(V600E) dependent anchorage independent growth and invasion of melanoma cells
por: Datar, Ila, et al.
Publicado: (2019)

Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
por: González-González, Rogelio, et al.
Publicado: (2020)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

Lack of Association of B-type Raf Kinase V600E Mutation with High-risk Tumor Features and Adverse Outcome in Conventional and Follicular Variants of Papillary Thyroid Carcinoma
por: Nair, C. Gopalakrishnan, et al.
Publicado: (2017)

Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
por: Bhargava, Ajay, et al.
Publicado: (2016)

Genetic targeting of B-Raf(V600E) affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells
por: Hirschi, Benjamin, et al.
Publicado: (2014)

Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance
por: Serasinghe, Madhavika N., et al.
Publicado: (2014)

The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes
por: Betancourt, Lazaro Hiram, et al.
Publicado: (2019)

B-RAF(V600E) Inhibitor Dabrafenib Attenuates RIPK3-Mediated Necroptosis and Promotes Functional Recovery after Spinal Cord Injury
por: Sugaya, Takehiro, et al.
Publicado: (2019)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

SMAD4 is Critical in Suppression of BRAF-V600E Serrated Tumorigenesis
por: Tong, Kevin, et al.
Publicado: (2021)

Black Rice Anthocyanins Suppress Metastasis of Breast Cancer Cells by Targeting RAS/RAF/MAPK Pathway
por: Chen, Xiang-Yan, et al.
Publicado: (2015)

Non-small Cell Lung Cancer With Proto-Oncogene B-Raf V600E Presenting a Distinctive Clinical Course: A Case Report
por: Sasada, Aosa, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1fbbolqlg3pp69bf5tsatv08bu